Company Overview and News

9
Japanese financial giants: PH samurai bonds to make a killing

2018-06-20 business.inquirer.net
Five large Japanese financial institutions are supporting the Philippines’ upcoming $1-billion samurai bond sale, the first issuance without a guarantee.
NMR 8604 N33 8306 NRSCF DSECF MUFG 8601 DSEEY MBFJF MTU

9
Banks see strong demand for PHL ‘samurai’ bonds

2018-06-20 bworldonline
TOP JAPANESE banks has expressed their interest in participating in the Philippines’ return to the yen debt market following a meeting with the Finance department in Tokyo.
MZHOF NMR DSECF 8604 N33 8306 NRSCF MUFG 8601 8411 DSEEY MBFJF MTU MFG

9
Top Japanese banks express support of Philippine “samurai bonds” following DoF meeting

2018-06-20 bworldonline
TOP JAPANESE BANKS have expressed their interest in participating in the Philippines’ return to the yen debt market following their meeting with the Finance department in Tokyo.
MZHOF NMR DSECF 8604 N33 8306 NRSCF MUFG 8601 8411 DSEEY MBFJF MTU MFG

17
Mercari’s top-of-range IPO set to make founder Shintaro Yamada a new Japanese billionaire

2018-06-11 japantimes.co.jp
Mercari Inc. priced its initial public offering at the top of the range to sell ¥130.5 billion ($1.2 billion) worth of shares, a valuation that’s set to make its 40-year-old founder a billionaire.
NMR MZHOF DSECF SMFG SMFNF YAHOF ZNGA 8604 N33 8316 8306 NRSCF 4689 MUFG 8601 YAHOY 8411 DSEEY MBFJF MTU MFG LN

2
China Harmonizes Booming Gas Market With Residential Price Hike - Bloomberg

2018-05-27 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
CGHLY CGASY DSECF 8601 DSEEY CGHOF 0384

7
Line, Marui and KDDI look for slice of the securities industry

2018-05-16 japantimes.co.jp
Companies in telecommunications, retail and other sectors are entering the securities industry in Japan, aiming to provide young people with financial services that can be conveniently used with credit cards or smartphones.
NMR 8604 N33 NRSCF DSECF 8601 DSEEY KDDIF LN KDDIY

2
Daiwa Securities Group, Inc. ADR 2017 Q4 - Results - Earnings Call Slides

2018-04-27 seekingalpha
The following slide deck was published by Daiwa Securities Group, Inc. ADR in conjunction with their 2017 Q4 earnings call.
DSECF 8601 DSEEY

5
Wynn's Pain Is Rivals' Gain With Macau Facing a Shakeup - Bloomberg

2018-03-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
2282 WYNN SCHYF DSECF WYNMF MCHVF GXYEF GXYYY 0880 SJMHY 1128 0027 MCHVY 1928 8601 DSEEY LVS SJMHF SCHYY GEBHF WYNMY

2
Brexit Bulletin: The Plot to Stop It - Bloomberg

2018-03-23 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
DLAR DLUEY DSECF 8601 DSEEY DELRF

6
Tokyo stocks turn lower on yen’s firmness

2018-03-16 japantimes.co.jp
Stocks turned lower on the Tokyo Stock Exchange on Friday, hurt by the yen’s rise against the dollar.
DKILY DSECF MRAAY TOELY DKILF KYO 6966 MRAAF 8601 DSEEY 6367 8035 TOELF

3
Speculation Mounts that Hong Kong's Richest Man Is About to Retire - Bloomberg

2018-03-13 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.
HTCTF HSE HTHKY CKHUF HGKGF DSECF 8601 HGKGY CKHUY DSEEY HUSKF

Related Articles

CASC: Cascadian Therapeutics Analysis and Research Report

2018-06-22 - Asif

Overview Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. The company's goal is to develop and commercialize novel targeted compounds that have the potential to improve the lives and outcomes of cancer patients. The company's lead clinical-stage product candidate is tucatinib, an oral, HER2-selective small molecule tyrosine kinase inhibitor. The company's pipeline also includes two preclinical-stage product candidates: CASC-578, a Chk1 kinase inhibitor, and CASC-674, an antibody program against an immuno-oncology target known as TIGIT. 2018 Merger Agreement On January 30, 2018, the company entered into an Agreement and Plan of Merger (the Merger Agreement) with Seattle Genetics, Inc., a Delaware corporation (Seattle Genetics), and Valley Acquisition Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Seattle Genetics (Merger Sub). Pursuant to the Merger ...

BAC: Bank of America Corp. Analysis and Research Report

2018-06-22 - Asif

Business Overview The Corporation is a Delaware corporation, a bank holding company (BHC) and a financial holding company. When used in this report, “the Corporation” may refer to Bank of America Corporation individually, Bank of America Corporation and its subsidiaries, or certain of Bank of America Corporation’s subsidiaries or affiliates. The company's principal executive offices are located in Charlotte, North Carolina. Through its banking and various nonbank subsidiaries throughout the U.S. and in international markets, the company provide a diversified range of banking and nonbank financial services and products through four business segments: Consumer Banking, Global Wealth & Investment Management (GWIM), Global Banking and Global Markets, with the remaining operations recorded in All Other. The company operate its banking activities primarily under the Bank of America, National Association (Bank of America, N.A. or BANA) charter. At March 31, 2018, the Corporation had a...

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

CUSIP: 234064301